Table 3 Correlation between expression of EMT and clinicopathological parameters in Kazakh ESCCs
Variable | Cases | E-cadherin low expression 0/1 + (%) | E-cadherin high expression 2+/3 + (%) | X2 | P | Vimentin low expression 0/1 + (%) | Vimentin high expression 2+/3 + (%) | X2 | P |
|---|---|---|---|---|---|---|---|---|---|
Age(y) | |||||||||
≤58 | 58 | 29(50%) | 29(50%) | 3.628 | 0.057 | 30(51.7%) | 28(48.3%) | 0.090 | 0.764 |
> 59 | 42 | 13(31%) | 29(69%) | 23(54.8%) | 19(45.2%) | ||||
Gender | |||||||||
Male | 62 | 30(48.4%) | 32(51.6%) | 2.732 | 0.098 | 26(41.9%) | 36(58.1%) | 8.109 | 0.005* |
Female | 38 | 12(31.6%) | 26(68.4%) | 27(71.1%) | 11(28.9%) | ||||
Differentiation | |||||||||
High | 26 | 9(34.6%) | 17(65.4%) | 0.055a | 0.814a | 13(50%) | 13(50%) | ||
Moderate | 47 | 15(31.9%) | 32(68.1%) | 8.382b | 0.004b# | 30(63.8%) | 17(36.2%) | 5.069 | 0.079 |
Poor | 27 | 18(66.7%) | 9(33.3%) | 5.445c | 0.020c | 1(37%) | 2(63%) | ||
Depth of invasion | |||||||||
T1-T2 | 29 | 3(10.3%) | 26(89.7%) | 16.802 | <0.001* | 25(86.2%) | 4(13.8%) | 18.081 | < 0.001* |
T3-T4 | 71 | 39(54.9%) | 32(45.1%) | 28(39.4%) | 43(60.6%) | ||||
Clinical stage | |||||||||
I-II | 65 | 19(29.2%) | 46(70.8%) | 12.431 | <0.001* | 45(69.2%) | 20(30.8%) | 19.640 | < 0.001* |
III-IV | 35 | 23(65.7%) | 12(34.3%) | 8(22.9%) | 27(77.1%) | ||||
Lymph node metastasis | |||||||||
pN- | 55 | 18(32.7%) | 37(67.3%) | 4.314 | 0.038* | 37(67.3%) | 18(32.7%) | 9.995 | 0.002* |
pN+ | 45 | 24(53.3%) | 21(46.7%) | 16(35.6%) | 29(64.4%) | ||||
Lymphatic metastasis | |||||||||
pN- | 32 | 7(21.9%) | 25(78.1%) | 7.824 | 0.005* | 23(71.9%) | 9(28.1%) | 6.730 | 0.009* |
pN+ | 68 | 35(51.5%) | 33(48.5%) | 30(44.1%) | 43(55.9%) | ||||